

(Company No : 680889-W)

SUNZEN BIOTECH BERHAD

(Incorporated in Malaysia)

**CONDENSED CONSOLIDATED STATEMENT OF PROFIT AND LOSS AND OTHER COMPREHENSIVE INCOME
FOR THE FINANCIAL PERIOD ENDED 30 SEPTEMBER 2015**

	Current Quarter Ended 30.09.2015 (Unaudited) RM'000	Corresponding Quarter Ended 30.09.2014 (Unaudited) RM'000	Current Year-To-Date Ended 30.09.2015 (Unaudited) RM'000	Corresponding Year-To-Date Ended 30.09.2014 (Unaudited) RM'000
Revenue	6,192	8,461	23,299	26,782
Operating profit	1,769	2,577	6,364	8,824
Operating expenses	(2,119)	(2,417)	(5,969)	(7,806)
Finance expenses	(60)	(75)	(187)	(235)
(Loss)/Profit before taxation	(410)	85	208	783
Tax expense	(58)	(77)	(105)	(231)
(Loss)/Profit after taxation	(468)	8	103	552
Other comprehensive income/(loss), net of tax <i>Items that may be reclassified subsequently to profit or loss</i>				
Surplus on revaluation of property	-	12,523	-	12,523
Foreign currency translation	(1)	(2)	26	42
	(1)	12,521	26	12,565
Total comprehensive (loss)/income	(469)	12,529	129	13,117
(Loss)/Profit after taxation attributable to owners of:				
- the Company	(467)	8	104	552
- non-controlling interest	(1)	-	(1)	-
	(468)	8	103	552
Total comprehensive (loss)/income attributable to owners of:				
- the Company	(468)	12,529	130	13,117
- non-controlling interest	(1)	-	(1)	-
	(469)	12,529	129	13,117
Earnings per share (sen) attributable to Owners of the Company:				
- Basic	(0.17)	0.00 ^	0.04	0.23

Note:-

^ 0.003 sen

The above condensed consolidated statement of profit and loss and other comprehensive income should be read in conjunction with the audited financial statements for the financial year ended 31 December 2014 and the accompanying explanatory notes attached to the interim financial statements.

(Company No : 680889-W)

SUNZEN BIOTECH BERHAD
(Incorporated in Malaysia)

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 30 SEPTEMBER 2015

	As At Financial Year Quarter 30.09.2015 (Unaudited) RM'000	As At Financial Year End 31.12.2014 (Audited) RM'000
ASSETS		
Non-current assets		
Property, plant and equipment	33,112	29,451
Product development expenditure	-	-
	<u>33,112</u>	<u>29,451</u>
Current assets		
Inventories	10,514	8,416
Trade receivables	6,922	6,578
Other receivables, deposits and prepayments	3,083	960
Tax refundable	991	608
Fixed and short term deposits with licensed banks	4,466	6,305
Cash and bank balances with licensed banks and other financial institution	6,406	8,934
	<u>32,382</u>	<u>31,801</u>
TOTAL ASSETS	<u>65,494</u>	<u>61,252</u>
EQUITY AND LIABILITIES		
Equity		
Share capital	29,374	16,577
Share premium	-	7,155
Treasury shares	(88)	(39)
Retained profits	16,935	19,394
Revaluation reserves	15,651	15,651
Merger deficit	(8,397)	(8,397)
Currency translation reserve	(4)	(30)
Attributable to owners of the Company	<u>53,471</u>	<u>50,311</u>
Non-controlling interest	29	-
TOTAL EQUITY	<u>53,500</u>	<u>50,311</u>
Non-current liabilities		
Deferred taxation	1,487	1,494
Hire purchase payables	115	221
Term loans	3,272	3,725
	<u>4,874</u>	<u>5,440</u>
Current Liabilities		
Trade payables	4,395	3,384
Bill payable	-	360
Other payables and accruals	2,062	1,083
Hire purchase payables	64	100
Term loans	598	574
Provision for taxation	1	-
	<u>7,120</u>	<u>5,501</u>
TOTAL LIABILITIES	<u>11,994</u>	<u>10,941</u>
TOTAL EQUITY AND LIABILITIES	<u>65,494</u>	<u>61,252</u>
Net assets per share (RM) attributable to owners of the Company	<u>0.18</u>	<u>0.30</u>

Note:-

The above condensed consolidated statement of financial position should be read in conjunction with the audited financial statements for the financial year ended 31 December 2014 and the accompanying explanatory notes attached to the interim financial statements.

The net assets per share attributable to owners of the Company is calculated based on net assets value divided by the number of ordinary shares in issue at the end of the reporting period of 293,738,098 (2014 - 165,618,666).

(Company No : 680889-W)

SUNZEN BIOTECH BERHAD
(Incorporated in Malaysia)

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE FINANCIAL PERIOD ENDED 30 SEPTEMBER 2015

	Share Capital RM'000	Share Premium RM'000	Treasury Shares RM'000	Revaluation Reserves RM'000	Merger Deficit RM'000	Currency Translation Reserve RM'000	Retained Profits RM'000	Attributable to owners of the Company RM'000	Non- Controlling Interest RM'000	Total Equity RM'000
Quarter ended 30 September 2015 (Unaudited)										
Balance at 1 January 2015	16,577	7,155	(39)	15,651	(8,397)	(30)	19,394	50,311	-	50,311
Profit after taxation for the financial period	-	-	-	-	-	-	104	104	(1)	103
Other comprehensive income for the financial period, net of tax:										
- Foreign currency translation	-	-	-	-	-	26	-	26	-	26
Total comprehensive income for the financial period	-	-	-	-	-	26	104	130	(1)	129
Issuance of shares	12,797	(7,155)	-	-	-	-	(2,563)	3,079	30	3,109
Purchase of own shares	-	-	(49)	-	-	-	-	(49)	-	(49)
Balance at 30 September 2015	29,374	-	(88)	15,651	(8,397)	(4)	16,935	53,471	29	53,500
Quarter ended 30 September 2014 (Unaudited)										
Balance at 1 January 2014	14,939	3,520	(14)	3,176	(8,397)	(98)	19,440	32,566	-	32,566
Profit after taxation for the financial period	-	-	-	-	-	-	552	552	-	552
Other comprehensive income for the financial period, net of tax:										
- Surplus on revaluation of property	-	-	-	12,523	-	-	-	12,523	-	12,523
- Foreign currency translation	-	-	-	-	-	42	-	42	-	42
Total comprehensive income for the financial period	-	-	-	12,523	-	42	552	13,117	-	13,117
Interim dividend of RM0.008 per ordinary share of RM0.10 each in respect of financial year ending 31 December 2014	-	-	-	-	-	-	(1,194)	(1,194)	-	(1,194)
Issuance of shares	1	(122)	-	-	-	-	-	(121)	-	(121)
Purchase of own shares	-	-	(14)	-	-	-	-	(14)	-	(14)
Balance at 30 September 2014	14,940	3,398	(28)	15,699	(8,397)	(56)	18,798	44,354	-	44,354

The above condensed consolidated statement of changes in equity should be read in conjunction with the audited financial statements for the financial year ended 31 December 2014 and the accompanying explanatory notes attached to the interim financial statements.

(Company No : 680889-W)

SUNZEN BIOTECH BERHAD
(Incorporated in Malaysia)

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE FINANCIAL PERIOD ENDED 30 SEPTEMBER 2015

	Current Year To Date Ended 30.09.2015 (Unaudited) RM'000	Corresponding Year To Date Ended 30.09.2014 (Unaudited) RM'000
Cash flows from/(for) operating activities		
Profit before taxation	208	783
Adjustments for:-		
Amortisation of product development expenditure	-	55
Depreciation of property, plant and equipment	601	439
Interest expense	178	222
Inventories written off	192	222
Write down of inventories	(457)	720
Gain on disposal of plant and equipment	(24)	-
Interest income	(166)	(61)
Provision for write off of receivables	-	416
Unrealised (gain)/loss on foreign exchange	(25)	38
Operating profit before working capital changes	<u>507</u>	<u>2,834</u>
Increase in inventories	(1,832)	(619)
(Increase)/Decrease in trade and other receivables	(2,463)	2,405
Increase/(Decrease) in trade and other payables	<u>1,637</u>	<u>(674)</u>
Cash (for)/from operations	<u>(2,151)</u>	<u>3,946</u>
Net tax paid	(495)	(723)
Interest paid	<u>(180)</u>	<u>(223)</u>
Net cash (for)/from operating activities	<u>(2,826)</u>	<u>3,000</u>
Cash flows from/(for) investing activities		
Interest received	166	61
Proceeds from disposal of plant and equipment	130	-
Purchase of property, plant and equipment	<u>(4,369)</u>	<u>(62)</u>
Net cash for investing activities	<u>(4,073)</u>	<u>(1)</u>
Cash flows from/(for) financing activities		
Repayment of term loans	(426)	(410)
Repayment to directors	-	(9)
Repayment of hire purchase obligations	(142)	(83)
Treasury shares	(49)	(14)
Dividend paid	-	(1,194)
Listing expenses	(197)	(122)
Issuance of shares	3,276	1
Proceeds from shares issued to non-controlling interest	30	-
Net cash from/(for) financing activities	<u>2,492</u>	<u>(1,831)</u>
Net (decrease)/increase in cash and cash equivalents	(4,407)	1,168
Cash and cash equivalents at beginning of the financial period	15,239	7,961
Foreign exchange difference	40	4
Cash and cash equivalents at end of the financial period	<u>10,872</u>	<u>9,133</u>
Cash and cash equivalents comprise:		
Fixed and short term deposits with licensed banks	4,466	2,277
Cash and bank balances with licensed banks and other financial institution	<u>6,406</u>	<u>6,856</u>
	<u>10,872</u>	<u>9,133</u>

Note:-

The above condensed consolidated statement of cash flows should be read in conjunction with the audited financial statements for the financial year ended 31 December 2014 and the accompanying explanatory notes attached to the interim financial statements.

SUNZEN BIOTECH BERHAD

(Company No: 680889-W)

(Incorporated in Malaysia)

NOTES TO THE INTERIM STATEMENTS FOR THE FINANCIAL PERIOD ENDED 30 SEPTEMBER 2015

A. NOTES PURSUANT TO THE MALAYSIAN FINANCIAL REPORTING STANDARD 134 (MFRS 134): INTERIM FINANCIAL REPORTING

A1. Basis of reporting preparation

The unaudited interim financial statements have been prepared in accordance with the Malaysian Financial Reporting Standards (“MFRSs”) 134: “Interim Financial Reporting” issued by the Malaysian Accounting Standards Board (“MASB”) and Chapter 9, Part K of the Listing Requirements of Bursa Malaysia Securities Berhad (“Bursa Securities”) for the ACE Market (“ACE LR”). The unaudited interim financial statements should be read in conjunction with the audited annual financial statements of the Group for the financial year ended 31 December 2014.

The following Amendments to MFRSs applicable to the Group have been adopted with effect from 1 January 2015. The adoption of the amendments did not have any material impacts on the financial statements of the Group.

- Amendment to MFRS 119, Defined Benefit Plans: Employee Contributions
- Annual Improvements to MFRSs 2010 - 2012 Cycle
- Annual Improvements to MFRSs 2011 - 2013 Cycle

The following revised MFRSs and Amendments to MFRSs issued by the MASB are not yet effective for adoption by the Group and are not expected to have any material impacts on the financial statements of the Group.

Amendments effective for financial periods beginning on or after 1 January 2016

- Annual Improvements to MFRSs 2012 - 2014 Cycle
- Amendment to MFRS 10 and MFRS 128, Sale or Contribution of Assets between an Investor and its Associate or Joint Venture
- Amendments to MFRS 11, Accounting for Acquisitions of Interests in Joint Operations
- MFRS 14, Regulatory Deferral Accounts
- Amendments to MFRS 101, Disclosure Initiative
- Amendments to MFRS 116 and MFRS 138, Clarification of Acceptance Methods of Depreciation and Amortisation
- Amendments to MFRS 116 and MFRS 141, Agriculture: Bearer Plants
- Amendments to MFRS 127, Equity Method in Separate Financial Statements
- Amendments to MFRS 10, MFRS 12 and MFRS 128, Investment Entities: Applying the Consolidation Exception

SUNZEN BIOTECH BERHAD

(Company No: 680889-W)

(Incorporated in Malaysia)

A1. Basis of reporting preparation (*Cont'd*)

Amendments effective for financial periods beginning on or after 1 January 2017

- MFRS 15, Revenue from Contracts with Customers

Amendments effective for financial periods beginning on or after 1 January 2018

- MFRS 9, Financial Instruments (IFRS 9 issued by IASB in July 2014)

A2. Auditors' report on preceding annual financial statements

The audited financial statements of the Company and its subsidiaries for the FYE 31 December 2014 were not subjected to any qualification.

A3. Seasonal or cyclical factors

The principal business operations of the Group were not significantly affected by seasonal or cyclical factors during the current quarter under review.

A4. Items of unusual nature and amount

There were no items affecting assets, liabilities, equity, net income or cash flows that were unusual because of their nature, size or incidence during the current quarter under review.

A5. Material changes in estimates

There were no material changes in estimates of amounts reported that will have a material effect in the current quarter under review.

A6. Issuances, cancellations, repurchase, resale and repayments of debt and equity securities

In the current quarter under review, there were conversions of 7,102,750 free Warrants 2014/2019 into ordinary shares of RM0.10 each, total number of ordinary shares in issue had increased to 293,738,098 shares. Balance number of treasury shares held as of 30 September 2015 were 248,000 shares with carrying amount of RM87,854.

A7. Dividend paid

There was no dividend payment made during the current quarter under review.

A8. Segmental information

Segmental revenue on the basis of geographical market is as follows:-

Geographical Market	Current Year-To-Date Ended 30 September 2015 RM'000	Corresponding Year-To-Date Ended 30 September 2014 RM'000
Asia other than Malaysia	4,763	6,620
Middle East	-	299
Total export revenue	4,763	6,919
Malaysia	18,536	19,863
Total export and local revenue	23,299	26,782

For current year-to-date, revenue contribution from export and domestic markets indicated a contraction of 31.16% and 6.68% respectively compared to a year earlier. Export revenue contributed about 20.44% of total revenue for current year-to-date versus 25.83% in the corresponding year.

A9. Valuation of property, plant and equipment

Revaluation of the Group's freehold lands and buildings has been brought forward without any amendments from the financial statement for FYE 31 December 2014.

A10. Capital commitments

At the end of the reporting date, there were no outstanding capital commitments not provided for in the interim statements under review.

A11. Material subsequent event after the Reporting Period

There were no material events subsequent to the end of the current quarter that have not been reflected in the financial statements, which are likely to substantially affect the current quarter results under review.

A12. Changes in the Composition of the Group

For the current quarter under review, there were no changes in the composition of the Group.

SUNZEN BIOTECH BERHAD
(Company No: 680889-W)
(Incorporated in Malaysia)

A13. Contingent Liabilities

Save for the following corporate guarantees, neither the Company nor its subsidiaries have any contingent liabilities at the end of the reporting period, which upon becoming enforceable, may have a material effect on the financial position of the Group.

The Company has placed a corporate guarantee amounting to RM17,131,000 in favour of Maybank Islamic Berhad in relation to Islamic banking facilities granted to Sunzen Corporation Sdn Bhd as follows:

Islamic Banking Facility	Corporate Guarantee RM'000	Facility Limit RM'000	Balance As At 30 September 2015 RM'000
Bank overdraft	500	500	-
Trade line	6,000	6,000	-
Term loans	10,631	6,465	3,870
Total.	17,131	12,965	3,870

The Company has also created a corporate guarantee in favour of Zuellig Pharma Sdn Bhd for due payment, all liabilities and obligation relating to supply of Zoetis products to Sunzen Corporation Sdn Bhd with credit limits of up to RM2.5 million.

B. ADDITIONAL INFORMATION REQUIRED UNDER THE ACE LR

B1. Review of performance of the Company and its principal subsidiaries for the current quarter and financial year-to-date

	Current Quarter Ended 30 September 2015 RM'000	Corresponding Quarter Ended 30 September 2014 RM'000	Current Year-To-Date Ended 30 September 2015 RM'000	Corresponding Year-To-Date Ended 30 September 2014 RM'000
Revenue	6,192	8,461	23,299	26,782
(Loss)/Profit before taxation ("PBT")	(410)	85	208	783

In the current quarter, the Group posted a 26.82% decrease in revenue contribution to RM6.19 million from RM8.46 million in the corresponding period of 2014, attributed to mainly the decrease in sales volume achieved for local and export markets in the current quarter. Current year-to-date's revenue was down by 13.01% or RM3.48 million compared to the previous year.

The fall in Group's revenue and higher products costs in respect of trading products in particular, have resulted in reporting a pre-tax loss of RM410,000 in the current quarter. PBT for current year-to-date was down by 73.44% to RM208,000 from RM783,000 in a year earlier.

B2. Review of performance of the operating segments of the Company and its principal subsidiaries for the current quarter and financial year-to-date

Revenue	Current Quarter Ended 30 September 2015 RM'000	Corresponding Quarter Ended 30 September 2014 RM'000	Current Year-To-Date Ended 30 September 2015 RM'000	Corresponding Year-To-Date Ended 30 September 2014 RM'000
Trading	2,280	4,162	10,338	13,369
Manufacturing	3,912	4,299	12,961	13,413
Total	6,192	8,461	23,299	26,782

SUNZEN BIOTECH BERHAD

(Company No: 680889-W)

(Incorporated in Malaysia)

Revenue from trading and manufacturing of animal health products was down by 45.22% and 9.00% respectively in the current quarter relative to corresponding period. For current year-to-date, trading product's revenue had decreased by 22.67% while manufacturing product was slightly down by 3.37% year-on-year.

B3. Profit before taxation

Profit before taxation is arrived at after (charging)/crediting:-

	Current Quarter Ended 30 September 2015 RM'000	Corresponding Quarter Ended 30 September 2014 RM'000	Current Year-To-Date Ended 30 September 2015 RM'000	Corresponding Year-To-Date Ended 30 September 2014 RM'000
Interest income	55	18	166	61
Interest expense	(58)	(72)	(178)	(222)
Depreciation and Amortisation	(292)	(187)	(601)	(494)
Provision for write off of receivables	-	-	-	(416)
Inventories written off	(3)	-	(192)	(222)
Write down of inventories	(59)	(435)	457	(720)
Gain on disposal of plant and property	-	-	24	-
Gain/(loss) on foreign exchange:				
- realised	80	48	151	106
- unrealised	(68)	4	25	(38)

B4. Material changes in the Current Quarter's results compared to the results of the immediate Preceding Quarter

	Current Quarter Ended 30 September 2015 RM'000	Preceding Quarter Ended 30 June 2015 RM'000	Variance	
			RM'000	%
Revenue	6,192	9,071	(2,879)	(31.74)
PBT	(410)	195	(605)	(310.26)

Group's revenue, quarter-on-quarter slipped by 31.74% to RM6.19 million in the third quarter ended 30 September 2015. PBT turned into a negative in the third quarter on lower sales volume and higher products costs in contrast with a pre-tax profit of RM195,000 in the preceding quarter.

SUNZEN BIOTECH BERHAD

(Company No: 680889-W)

(Incorporated in Malaysia)

B5. Prospects

There has been a steady growth in the consumption of animal feeds in livestock industry with the increased consumption of livestock products in tandem with growing global population, economic affluence as well as our government's initiatives to promote national food safety and self-sufficiency of livestock, which are likely to boost the livestock industry. Based on above positive trend for livestock industry and the on-going expansion plans the Group embarked on, it is of the view that the outlook of the Group is expected to be promising.

B6. Profit forecast and profit guarantee

No profit forecast or profit guarantee has been issued by the Group for the current quarter under review.

B7. Taxation

	Current Quarter Ended 30 September 2015 RM'000	Corresponding Quarter Ended 30 September 2014 RM'000	Current Year-To-Date Ended 30 September 2015 RM'000	Corresponding Year-To-Date Ended 30 September 2014 RM'000
<u>Income tax expense:-</u>				
Current financial year	58	32	111	205
Overprovision in previous financial year	-	-	-	-
	<u>58</u>	<u>32</u>	<u>111</u>	<u>205</u>
<u>Deferred tax expense:-</u>				
Current financial year	-	45	(6)	26
	-	45	(6)	26
Tax expense	<u>58</u>	<u>77</u>	<u>105</u>	<u>231</u>

The Company's wholly-owned subsidiary, Sunzen LifeSciences Sdn. Bhd. was awarded the BioNexus status incentive under the Promotion of Investment Act, 1986 by the Ministry of Finance, with the recommendation made by Malaysian Biotechnology Corporation Sdn. Bhd. on 23 July 2007. Accordingly, the subsidiary is granted 100% tax exemption from the statutory income derived from the production of in-feed anti bacterial products and supplements for animal health products for a period of 10 years commencing from 1 January 2010 to 31 December 2019.

B8. Status of Corporate Proposal

Bursa Securities had, vide its letter dated 20 October 2015, granted its approval on the following:

- (a) admission to Official List of Bursa Securities for up to 192,579,515 Warrants to be issued pursuant to the Proposed Rights Issue of Shares with Warrants; and
- (b) listing of and quotation for:
 - (i) up to 192,579,515 Rights Shares;
 - (ii) up to 5,327,525 Adjustment Warrants (subject to a final revision);
 - (iii) such number of additional new Sunzen Shares, representing up to 30% of the issued and paid-up capital of Sunzen (excluding treasury shares) to be issued for the exercise of SIS Options pursuant to the Proposed SIS; and
 - (iv) up to 197,907,040 new Sunzen Shares to be issued pursuant to the exercise of up to 192,579,515 Warrants and up to 5,327,525 Adjustment Warrants (subject to a final revision).

Warrants 2014/2019 with exercise right expiring on 14 April 2019

At year-to-date ended 30 September 2015, total number of Warrants 2014/2019 that had converted into ordinary shares at RM0.10 each and the number of unexercised warrants as follows:

Total number of warrants listed	Total number of warrants converted into ordinary shares	Total number of unexercised warrants
61,486,246	34,258,485	27,227,761

B8. Status of Corporate Proposal (Cont'd)

Utilisation of Private Placement proceeds

As at the announcement date of this report, the total gross proceeds of RM5.356 million raised from Private Placement of 14,880,000 ordinary shares placed out at RM0.36 each has been fully utilised as follows:

Purpose	Proposed utilisation RM'000	Actual utilisation RM'000	Intended timeframe for utilisation from the listing date* (Months)	Deviation		Explanation
				RM'000	%	
Upgrading/ purchase of plant and machinery	5,181	5,244	24	(63)		
Estimated listing expenses	175	112	0.5	63		Note ⁽¹⁾
Total	5,356	5,356		-		

Notes:

* Listing of Placement Shares on 14 November 2014.

(1) The surplus amount of the listing expenses incurred has been adjusted to the upgrading/purchase of plant and machinery.

B9. Group borrowings and debt securities

The Group's borrowings as at 30 September 2015 were as follows:

	Secured RM'000	Unsecured RM'000	Total RM'000
<u>Short-term borrowings:-</u>			
Bills payable	-	-	-
Hire purchases	64	-	64
Term loans	598	-	598
	<u>662</u>	<u>-</u>	<u>662</u>
	Secured RM'000	Unsecured RM'000	Total RM'000
<u>Long-term borrowings:-</u>			
Hire purchases	115	-	115

SUNZEN BIOTECH BERHAD
(Company No: 680889-W)
(Incorporated in Malaysia)

Term loans	3,272	-	3,272
	3,387	-	3,387
Total	4,049	-	4,049

The above borrowings are denominated in Ringgit Malaysia.

B10. Material Litigation

As at the date of this announcement, neither the Company nor any of its subsidiaries is engaged in any material litigation and arbitration either as plaintiff or defendant, which has a material effect on the financial position of the Company or its subsidiaries and the Directors are not aware of any proceedings pending or threatened or of any facts likely to give rise to any proceedings which might materially and adversely affect the financial position or business of the Company or its subsidiaries.

B11. Dividend declared or recommended

There was no dividend declared by the Board in the current quarter.

B12. Earnings per share

Basic earnings per share is calculated by dividing the Group's profit after taxation attributable to owners of the Company for the period over the weighted average number of ordinary shares in issue excluding treasury shares during the financial period. For comparative purpose, basic earnings per share for the corresponding period is restated to take Bonus Issue of shares into consideration.

	Current Quarter Ended 30 September 2015	Corresponding Quarter Ended 30 September 2014	Current Year-To-Date Ended 30 September 2015	Corresponding Year-To-Date Ended 30 September 2014
Group's (loss)/profit after taxation attributable to owners of the Company (RM'000)	(468)	8	103	552
Weighted average number of ordinary shares in issue excluding treasury shares	274,466,816	244,504,613	274,466,816	244,504,613
Basic earnings per share (sen)	(0.17)	0.00 [^]	0.04	0.23

Note:-

[^] 0.003 sen

SUNZEN BIOTECH BERHAD
(Company No: 680889-W)
(Incorporated in Malaysia)

B13. Disclosure of Realised and Unrealised Profits or Losses

The breakdown of the retained profits of the Group at the end of the reporting period is presented in accordance with the directive issued by Bursa Securities and prepared in accordance with Guidance on Special Matter No. 1, Determination of Realised and Unrealised Profits or Losses in the Context of Disclosure Pursuant to Bursa Securities Listing Requirements, as issued by the Malaysian Institute of Accountants.

	Current Year-To-Date Ended 30 September 2015 RM'000	Corresponding Year-To-Date Ended 30 September 2014 RM'000
Total retained profits of the Group:-		
- realised	18,345	20,280
- unrealised	(1,410)	(1,482)
Group's retained profits as per consolidated financial statements	16,935	18,798

This quarterly report for the financial period ended 30 September 2015 has been seen and approved by the Board of Directors of Sunzen Biotech for release to Bursa Securities.

Date: 24 November 2015